In this study, we systematically (1) evaluated the in vitro efficacy of stachydrine on CML cell lines and stem/progenitor cells from BP-CML patients; (2) determined the combinatory effects of stachydrine and BCR-ABL TKI; (3) investigated the selective activity of stachydrine using normal cord blood (CB) cells; (4) analysed the underlying mechanisms of stachydrine focussing on receptor tyrosine kinase (TRK) pathways. Here, NTRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.